SG11202011815SA - Combination therapy for treating hepatitis b virus infection - Google Patents

Combination therapy for treating hepatitis b virus infection

Info

Publication number
SG11202011815SA
SG11202011815SA SG11202011815SA SG11202011815SA SG11202011815SA SG 11202011815S A SG11202011815S A SG 11202011815SA SG 11202011815S A SG11202011815S A SG 11202011815SA SG 11202011815S A SG11202011815S A SG 11202011815SA SG 11202011815S A SG11202011815S A SG 11202011815SA
Authority
SG
Singapore
Prior art keywords
combination therapy
virus infection
treating hepatitis
hepatitis
treating
Prior art date
Application number
SG11202011815SA
Inventor
Antoine Alam
Odile Bonnin
Kara Carter
Julie Montegut
Cendrine Lemoine
Xavier Marniquet
Original Assignee
Sanofi Sa
Evotec Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Evotec Int Gmbh filed Critical Sanofi Sa
Publication of SG11202011815SA publication Critical patent/SG11202011815SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG11202011815SA 2018-06-01 2019-05-31 Combination therapy for treating hepatitis b virus infection SG11202011815SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305675 2018-06-01
PCT/EP2019/064239 WO2019229264A1 (en) 2018-06-01 2019-05-31 Combination therapy for treating hepatitis b virus infection

Publications (1)

Publication Number Publication Date
SG11202011815SA true SG11202011815SA (en) 2020-12-30

Family

ID=62567572

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011815SA SG11202011815SA (en) 2018-06-01 2019-05-31 Combination therapy for treating hepatitis b virus infection

Country Status (10)

Country Link
US (1) US20210260165A1 (en)
EP (1) EP3801598A1 (en)
JP (1) JP2021525761A (en)
CN (1) CN112912098A (en)
AU (1) AU2019276372A1 (en)
BR (1) BR112020024179A2 (en)
CA (1) CA3102182A1 (en)
IL (1) IL279078A (en)
SG (1) SG11202011815SA (en)
WO (1) WO2019229264A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230028476A1 (en) * 2019-12-03 2023-01-26 Evotec International Gmbh Interferon-associated antigen binding proteins for use in treating hepatitis b infection

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2703893B2 (en) 1985-07-05 1998-01-26 ホワイトヘッド・インスティテュ−ト・フォ−・バイオメディカル・リサ−チ Epithelial cells expressing foreign genetic material
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
EP0378576B1 (en) 1987-09-11 1995-01-18 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
JP2914692B2 (en) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ Endothelial cell genetic modification
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
JP3249516B2 (en) 1990-10-31 2002-01-21 ソマティクス セラピー コーポレイション Retroviral vectors for gene therapy
CA2129533A1 (en) * 1992-02-10 1993-08-19 Douglas Testa Improved alpha interferon composition and method for its production from human peripheral blood leukocytes
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US7993648B2 (en) * 2006-05-03 2011-08-09 The Regents of the Universitry of Colorado Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
US9272029B2 (en) * 2009-03-26 2016-03-01 Ibc Pharmaceuticals, Inc. Interferon lambada-antibody complexes
US20140004079A1 (en) * 2012-06-21 2014-01-02 Agency For Science, Technology And Research In vivo dendritic cell therapeutic adjuvant
CA2874864C (en) * 2012-08-14 2023-02-21 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
WO2016112983A1 (en) 2015-01-15 2016-07-21 Biontech Ag Cytokine fusion proteins
WO2018087345A1 (en) * 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
CN106701825A (en) * 2016-11-17 2017-05-24 中国科学院生物物理研究所 Adenovirus vaccine Ad-LIGHT-HBsAg and purpose thereof for treating chronic hepatitis B

Also Published As

Publication number Publication date
AU2019276372A1 (en) 2020-12-24
JP2021525761A (en) 2021-09-27
US20210260165A1 (en) 2021-08-26
BR112020024179A2 (en) 2021-03-30
CA3102182A1 (en) 2019-12-05
AU2019276372A2 (en) 2021-01-07
IL279078A (en) 2021-01-31
EP3801598A1 (en) 2021-04-14
CN112912098A (en) 2021-06-04
WO2019229264A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
HUS2200053I1 (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
HK1251219A1 (en) Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection
ZA201900156B (en) Phosphoramidates for the treatment of hepatitis b virus
IL312809A (en) Methods for treating hepatitis b infection
EP3332007A4 (en) Rnai therapy for hepatitis b virus infection
IL277745A (en) Use of fubp1 inhibitors for treating hepatitis b virus infection
HUE054191T2 (en) Treatment of hepatitis delta virus infection
ZA202100141B (en) Aryl-n-aryl derivatives for treating a rna virus infection
SG11202000347UA (en) A composition for treating and/or preventing hepatitis b virus infection and the use thereof
GB201803197D0 (en) Viral treatment
IL279078A (en) Combination therapy for treating hepatitis b virus infection
IL271491A (en) Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
PL4021505T3 (en) Medicament for treating infectious diseases
EP3894402C0 (en) N-containing chromen-4-one derivatives for the treatment and prophylaxis of hepatitis b virus infection
GB201816547D0 (en) Oncolytic virus for the treatment of cancer
GB201917498D0 (en) Treatment o f hepatitis b virus (hbv) infection
EP3849966C0 (en) Flavone compounds for the treatment and prophylaxis of hepatitis b virus disease